A Phase II Trial of PSMA ADC in Taxane-Treated mCRPC

Daniel P. Petrylak, MD, discusses a phase II trial of prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-treated metastatic castration-resistant prostate cancer (mCRPC).

Clinical Pearls

Daniel P. Petrylak, MD, director, Prostate and GU Medical Oncology, Yale Cancer Center, discusses a phase II trial of prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-treated metastatic castration-resistant prostate cancer (mCRPC) presented at the 2014 AUA Annual Meeting.

  • Patients with progressive mCRPC progressing after taxane treatment and ECOG PS 0 or 1 were treated with PSMA ADC every 3 weeks.
  • Early on, researchers learned that 2.5 mg/kg was too high of a dose and reduced it to 2.3 mg/kg for remaining patients.
  • Patients who expressed PSMA on circulating tumor cells and had lack of neuroendocrine markers tended to respond to the antibody complex.
  • PSMA ADC was fairly well tolerated. The most common significant adverse events observed were neutropenia and peripheral neuropathy.